Selective Accumulation of Boron-conjugated Liposomes Com-posed of Dimyristoylphosphatidylcholine to B16F10 Murine Mel-anoma Cells in Relation to Fluidity of Cell Membranes.
Project/Area Number |
15K15463
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Radiation science
|
Research Institution | Hiroshima International University |
Principal Investigator |
|
Research Collaborator |
Masunaga Shinichiro 京大原子炉
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
Keywords | リポソーム / 中性子捕捉療法 / 膜流動性 / 膜流動感受性 / BNCT / 細胞透過性ペプチド / ハイブリッド / DDS |
Outline of Final Research Achievements |
Membrane-fluidity sensitive boron liposomes (MFSBLs) had a mean diameter of 59.6 nm and a zeta potential of -11.3 mV. High encapsulation efficiency value from 55% to 89% of B-10 in MFSBLs were obtained. MFSBLs had high stability (95-99%) in the retention of B-10 during storage at 4°C for 30 d. All borocap-tate-loaded formulations had low cytotoxic effects in human fibroblast cells. MFSBLs were efficiently fused to melanoma cells, but were inefficiently fused to human fibroblast cells. Thus, it is essential to elevate the B-10 concentration in melanoma cells, while maintain low levels of B-10 in normal fibroblast cells. The tumor/normal ratio (T/N ratio) was 3.0. MFSBLs showed higher suppression of growth of melanoma cells than BSH solution. This result suggested novel MFSBLs composed of DMPC is useful for B-10 carrier on BNCT for melanoma.
|
Report
(4 results)
Research Products
(2 results)